TapImmune Inc. is a biotechnology company headquartered in Bellevue, Washington. They specialize in the development of immunotherapeutic vaccines for cancer and infectious diseases. Their core business focus is on emerging technologies based on cellular immunology and genetic understanding of the cause and potential novel treatments of disease.

TapImmune Inc.’s lead product is the TAP vaccine. It performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers. Therefore, the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In addition, the TAP molecule works as an adjuvant (accelerant) to enhance targeted vaccines against infectious diseases.

The Company is developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The expectation is that the global vaccine market will grow from $13 billion in 2007 to $21 billion

...

Recently, Dendreon Corp. (DNDN) announced that it intends to file an amendment to its existing Biologic License Application (BLA) for its prostate cancer vaccine Provenge in Nov. 2009. We believe that the US Food and Drug Administration (FDA) will approve Provenge in the first half of 2010 based on the positive phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results announced in Apr. 2009.   If approved, Dendreon will become the first company to receive approval for an anti-cancer immunotherapy based vaccine. In development studies, Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Unlike traditional vaccines that prevent diseases, Provenge treats it by stimulating the body's own immune system to attack cancer cells. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S.   Prostate cancer ...

The procedure has been called “one of the most barbaric mistakes ever perpetrated by mainstream medicine.” Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.

This was the early method of performing a lobotomy. And just 50 years ago, they were carried out not only on severely mentally ill people, but also on moody teenagers, or housewives who’d lost their enthusiasm for domestic work. Seriously. Over 40,000 Americans were lobotomized, often with catastrophic results.

Thankfully, they’re a thing of the past. But it made me think about how medicine has changed over the years and what practices were once acceptable. Just a few hundred years ago, for example, you wouldn’t have questioned the “doctor” for putting leeches on you any more than you do today for prescribing an antibiotic.

What other

...

Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

...

Dendreon Corporation (DNDN) is likely to become the first company to receive approval from the US Food and Drug  Administration (FDA) for an anti-cancer, immunotherapy based vaccine, as it released phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results for its key product candidate, Provenge, in April 2009. Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of 2009. We believe that the FDA will approve Provenge in the first half of 2010 based on the positive late-stage study results. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S. We believe Provenge could have blockbuster potential if it is approved by the regulators. Prostate cancer is the most ...

Adeona Pharmaceuticals, Inc.

(Public, AMEX:AEN)

StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, Oral dnaJP1 which is an immunotherapy for rheumatoid arthritis (RA) patients. If these products aren’t enough to entice your way into purchasing this stock, take a look at the recent $5 million dollar cash infusion from the National Multiple Sclerosis Society (NMSS), billions of dollars in product market potential, purchasing of Hartlab LLC, an independent Chicago-area CLIA-certified clinical reference laboratory, an experienced management team that will have you feeling like a kid in a candy store, and to

...

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

...

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Friday August 28, 2009

PennyOmega.com Stock Report!

**************************************************************

The Farmers National Bank of Emlenton, the subsidiary operating bank of Emclaire Financial Corp. (OTCBB: EMCF), announced today that the Bank completed its acquisition of the full-service branch office of National City Bank (”National City”), now a part of The PNC Financial Services Group, Inc. (NYSE: PNC), located in Titusville, Pennsylvania. The office will open for full service as a Farmers National Bank office on Monday, August 31, 2009.

Seamless Corporation (OTCBB: SMWF) announced today that it and one of America’s favorite product promoters, Dr. Gadget, further solidified their relationship by Seamless’ acquisition of www.gadgetenterprises.com, an eCommerce website. Terms

...

Companies featured in this edition of the newsletter: CUR, CVM, DKAM, ICLK, IMUC, IWEB, OMCM, ONEZ, SVUL, TAGS

Markets managed to extend their run this week, hitting fresh highs for ‘09 despite coming under pressure from negative economic reports and a significant two week correction in Chinese equity markets. All told, the Dow ended up 2.0%, gaining 184 points to close at 9505, extending its yearly gains to 8.3%. The Nasdaq finished the week up 1.8%, closing back above 2000 at 2020, up 28.1% on the year, while the S&P 500 and Russell 2000 managed to post gains of 2.2% and 3.1% respectively, bringing their yearly gains to 13.6% and 16.4%.

Concerns stemming from weakness in Chinese markets which have surrendered 20% in the past two weeks after climbing 109% from October lows spooked many investors expecting a similar correction in US markets early in the week. US

...